Incyte Genomics Inc
Veridion Score
Composite trend over time
Why is INCY moving today?
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for INCY.
INCY insider activity
Incyte Genomics Inc
5 insiders bought in the last 90 days
Net selling: -$42.2M across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-08 | 2026-06-04 | Tray Thomas | Insider | sell | $100.00 | 2,639 | 21,132 | $264K | SEC Form 4 |
| 2026-06-08 | 2026-06-04 | Tray Thomas | Insider | buy | $83.83 | 2,639 | 23,771 | $221K | SEC Form 4 |
| 2026-06-03 | 2026-06-01 | CAGNONI PABLO J | Insider | sell | $95.59 | 25,469 | 240,848 | $2.4M | SEC Form 4 |
| 2026-05-28 | 2026-05-26 | Tray Thomas | Insider | sell | $97.35 | 2,051 | 21,132 | $200K | SEC Form 4 |
| 2026-05-28 | 2026-05-26 | BIENAIME JEAN JACQUES | Insider | sell | $97.10 | 13,059 | 22,782 | $1.3M | SEC Form 4 |
Showing 5 recent rows. Sovereign unlocks 97 additional rows, full sorting, and the named-filer history.
Upgrade to Sovereign · $25/moINCY contract awards, year to date.
Public federal awards linked to this ticker.
INCY lobbying filings, year to date.
Registered lobbying filings matched to Incyte Genomics Inc.